ArticleCancer immunology, immunotherapy : CII2021

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.

Emma H A Stahlie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.